课题基金 / 基金详情

Basis for Androgen Receptor Antagonist Resistance in CRPC

Basis for Androgen Receptor Antagonist Resistance in CRPC
CRPC 雄激素受体拮抗剂耐药的基础
批准号：
8475911
负责人：
Steven P. Balk
金额：
$29.28万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
项目状态：
已结题
起止时间：
2013-05-24 至 2018-04-30
来源：
https://reporter.nih.gov/project-details/8475911
关键词：
Androgen ReceptorAndrogensBicalutamideBindingCancer PatientCell NucleusChromatinDevelopmentFlutamideInstructionLigandsMalignant neoplasm of prostateMediatingNew AgentsNilutamideOncologistProteinsRecruitment ActivityRelapseResistanceabirateronearmbasecastration resistant prostate cancermennuclear receptor co-repressorresistance mechanismtherapeutic target

项目摘要

项目成果

Steven P. Balk的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
.. Currently available AR antagonists such as bicalutamide have limited activity in castration-resistant prostate cancer (CRPC). Mechanistic studies have shown that the bicalutamide liganded AR can accumulate in the nucleus and bind to chromatin, but that it does not effectively recruit coactivator proteins and instead can recruit the corepressor proteins NCoR and SMRT. This ability to mediate chromatin binding may be an
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DF/HCC Prostate SPORE
  • 批准号：
    10628270
  • 项目类别：
  • 资助金额：
    $258.56万
  • 财政年份：
    2023
  • 负责人：
    Steven P. Balk
  • 依托单位：
    DANA-FARBER CANCER INST
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer
Enhancing the Efficacy of Docetaxel in Prostate Cancer
Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs
海外基金